nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—PTGS2—bone cancer	0.47	1	CbGaD
Lenalidomide—PTGS2—Cisplatin—bone cancer	0.0604	0.566	CbGbCtD
Lenalidomide—TNFSF11—Osteoclast Signaling—TNFRSF11A—bone cancer	0.033	0.411	CbGpPWpGaD
Lenalidomide—TNFSF11—jaw skeleton—bone cancer	0.0243	0.159	CbGeAlD
Lenalidomide—ABCB1—Cisplatin—bone cancer	0.0199	0.187	CbGbCtD
Lenalidomide—TNFSF11—periosteum—bone cancer	0.0184	0.12	CbGeAlD
Lenalidomide—TNFSF11—skull—bone cancer	0.0151	0.0988	CbGeAlD
Lenalidomide—TNFSF11—leg—bone cancer	0.0146	0.0958	CbGeAlD
Lenalidomide—TNFSF11—forelimb—bone cancer	0.0145	0.0951	CbGeAlD
Lenalidomide—ABCB1—Doxorubicin—bone cancer	0.0134	0.125	CbGbCtD
Lenalidomide—TNFSF11—hindlimb—bone cancer	0.0131	0.0856	CbGeAlD
Lenalidomide—ABCB1—Methotrexate—bone cancer	0.0129	0.121	CbGbCtD
Lenalidomide—TNFSF11—cartilage tissue—bone cancer	0.0129	0.0842	CbGeAlD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—TNFRSF11A—bone cancer	0.0123	0.153	CbGpPWpGaD
Lenalidomide—TNFSF11—appendage—bone cancer	0.0112	0.0734	CbGeAlD
Lenalidomide—CDH5—S1P2 pathway—GNA11—bone cancer	0.00574	0.0715	CbGpPWpGaD
Lenalidomide—TNFSF11—Differentiation Pathway—IL3—bone cancer	0.0042	0.0524	CbGpPWpGaD
Lenalidomide—TNFSF11—connective tissue—bone cancer	0.0032	0.021	CbGeAlD
Lenalidomide—TNFSF11—Differentiation Pathway—KIT—bone cancer	0.00245	0.0306	CbGpPWpGaD
Lenalidomide—CDH5—connective tissue—bone cancer	0.00241	0.0158	CbGeAlD
Lenalidomide—PTGS2—periosteum—bone cancer	0.00239	0.0156	CbGeAlD
Lenalidomide—TNFSF11—tendon—bone cancer	0.0022	0.0144	CbGeAlD
Lenalidomide—TNFSF11—bone marrow—bone cancer	0.00213	0.014	CbGeAlD
Lenalidomide—CDH5—S1P2 pathway—JUN—bone cancer	0.00208	0.0259	CbGpPWpGaD
Lenalidomide—Pomalidomide—CYP3A4—bone cancer	0.00191	0.383	CrCbGaD
Lenalidomide—PTGS2—leg—bone cancer	0.0019	0.0125	CbGeAlD
Lenalidomide—Pomalidomide—PTGS2—bone cancer	0.00187	0.375	CrCbGaD
Lenalidomide—TNFSF11—IL6-mediated signaling events—JUN—bone cancer	0.00171	0.0213	CbGpPWpGaD
Lenalidomide—PTGS2—hindlimb—bone cancer	0.0017	0.0111	CbGeAlD
Lenalidomide—PTGS2—cartilage tissue—bone cancer	0.00167	0.011	CbGeAlD
Lenalidomide—CDH5—tendon—bone cancer	0.00166	0.0108	CbGeAlD
Lenalidomide—CDH5—bone marrow—bone cancer	0.0016	0.0105	CbGeAlD
Lenalidomide—CDH5—spinal cord—bone cancer	0.0016	0.0105	CbGeAlD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—JUN—bone cancer	0.00151	0.0188	CbGpPWpGaD
Lenalidomide—PTGS2—appendage—bone cancer	0.00146	0.00955	CbGeAlD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—BRAF—bone cancer	0.00132	0.0165	CbGpPWpGaD
Lenalidomide—ABCB1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00128	0.0159	CbGpPWpGaD
Lenalidomide—Thalidomide—PTGS2—bone cancer	0.0012	0.242	CrCbGaD
Lenalidomide—ABCB1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.0012	0.0149	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.00119	0.0149	CbGpPWpGaD
Lenalidomide—CRBN—tendon—bone cancer	0.00105	0.00688	CbGeAlD
Lenalidomide—CRBN—bone marrow—bone cancer	0.00102	0.00667	CbGeAlD
Lenalidomide—CRBN—spinal cord—bone cancer	0.00101	0.00664	CbGeAlD
Lenalidomide—ABCB1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000699	0.00871	CbGpPWpGaD
Lenalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000687	0.00857	CbGpPWpGaD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL3—bone cancer	0.000643	0.00802	CbGpPWpGaD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—ATF1—bone cancer	0.000567	0.00707	CbGpPWpGaD
Lenalidomide—ABCB1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000421	0.00525	CbGpPWpGaD
Lenalidomide—PTGS2—connective tissue—bone cancer	0.000416	0.00273	CbGeAlD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL3—bone cancer	0.000416	0.00519	CbGpPWpGaD
Lenalidomide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—bone cancer	0.000413	0.00515	CbGpPWpGaD
Lenalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000401	0.005	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—RGS1—bone cancer	0.000324	0.00404	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—GRM4—bone cancer	0.000324	0.00404	CbGpPWpGaD
Lenalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—DHFR—bone cancer	0.000315	0.00393	CbGpPWpGaD
Lenalidomide—PTGS2—tendon—bone cancer	0.000286	0.00187	CbGeAlD
Lenalidomide—CDH5—Signaling Pathways—GRM1—bone cancer	0.000281	0.0035	CbGpPWpGaD
Lenalidomide—PTGS2—bone marrow—bone cancer	0.000277	0.00182	CbGeAlD
Lenalidomide—PTGS2—spinal cord—bone cancer	0.000276	0.00181	CbGeAlD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—bone cancer	0.000258	0.00321	CbGpPWpGaD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—bone cancer	0.000257	0.0032	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.00024	0.00299	CbGpPWpGaD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—bone cancer	0.000221	0.00276	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000202	0.00252	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—SMO—bone cancer	0.000198	0.00247	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—GNA11—bone cancer	0.000181	0.00226	CbGpPWpGaD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.000175	0.00218	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000172	0.00214	CbGpPWpGaD
Lenalidomide—ABCB1—bone marrow—bone cancer	0.000172	0.00112	CbGeAlD
Lenalidomide—ABCB1—spinal cord—bone cancer	0.000171	0.00112	CbGeAlD
Lenalidomide—CDH5—Signaling Pathways—ATF1—bone cancer	0.000168	0.0021	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—bone cancer	0.000166	0.00207	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IL3—bone cancer	0.000164	0.00205	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—KIT—bone cancer	0.00016	0.002	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000156	0.00195	CbGpPWpGaD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—bone cancer	0.000146	0.00182	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000143	0.00178	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000142	0.00177	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.00014	0.00175	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TGFBR2—bone cancer	0.00014	0.00175	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.00014	0.00174	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IGF1R—bone cancer	0.000132	0.00165	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CDK4—bone cancer	0.00013	0.00162	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000122	0.00152	CbGpPWpGaD
Lenalidomide—Erythema multiforme—Methotrexate—bone cancer	0.000121	0.000653	CcSEcCtD
Lenalidomide—Neuropathy peripheral—Doxorubicin—bone cancer	0.000121	0.000653	CcSEcCtD
Lenalidomide—Haemoglobin—Epirubicin—bone cancer	0.00012	0.00065	CcSEcCtD
Lenalidomide—Stomatitis—Doxorubicin—bone cancer	0.00012	0.00065	CcSEcCtD
Lenalidomide—Rhinitis—Epirubicin—bone cancer	0.00012	0.000648	CcSEcCtD
Lenalidomide—Conjunctivitis—Doxorubicin—bone cancer	0.00012	0.000648	CcSEcCtD
Lenalidomide—Urinary tract infection—Doxorubicin—bone cancer	0.00012	0.000648	CcSEcCtD
Lenalidomide—Haemorrhage—Epirubicin—bone cancer	0.00012	0.000646	CcSEcCtD
Lenalidomide—Hepatitis—Epirubicin—bone cancer	0.00012	0.000646	CcSEcCtD
Lenalidomide—Eye disorder—Methotrexate—bone cancer	0.000119	0.000646	CcSEcCtD
Lenalidomide—Tinnitus—Methotrexate—bone cancer	0.000119	0.000644	CcSEcCtD
Lenalidomide—Hypoaesthesia—Epirubicin—bone cancer	0.000119	0.000643	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000119	0.00148	CbGpPWpGaD
Lenalidomide—Asthenia—Cisplatin—bone cancer	0.000119	0.000642	CcSEcCtD
Lenalidomide—Pharyngitis—Epirubicin—bone cancer	0.000119	0.000642	CcSEcCtD
Lenalidomide—Cardiac disorder—Methotrexate—bone cancer	0.000119	0.000641	CcSEcCtD
Lenalidomide—Sweating—Doxorubicin—bone cancer	0.000118	0.000639	CcSEcCtD
Lenalidomide—Urinary tract disorder—Epirubicin—bone cancer	0.000118	0.000638	CcSEcCtD
Lenalidomide—Oedema peripheral—Epirubicin—bone cancer	0.000118	0.000637	CcSEcCtD
Lenalidomide—Haematuria—Doxorubicin—bone cancer	0.000118	0.000635	CcSEcCtD
Lenalidomide—Connective tissue disorder—Epirubicin—bone cancer	0.000118	0.000635	CcSEcCtD
Lenalidomide—Urethral disorder—Epirubicin—bone cancer	0.000117	0.000634	CcSEcCtD
Lenalidomide—Hepatobiliary disease—Doxorubicin—bone cancer	0.000117	0.00063	CcSEcCtD
Lenalidomide—Epistaxis—Doxorubicin—bone cancer	0.000116	0.000628	CcSEcCtD
Lenalidomide—Angiopathy—Methotrexate—bone cancer	0.000116	0.000627	CcSEcCtD
Lenalidomide—Sinusitis—Doxorubicin—bone cancer	0.000116	0.000625	CcSEcCtD
Lenalidomide—Immune system disorder—Methotrexate—bone cancer	0.000115	0.000624	CcSEcCtD
Lenalidomide—Visual impairment—Epirubicin—bone cancer	0.000115	0.000623	CcSEcCtD
Lenalidomide—Mediastinal disorder—Methotrexate—bone cancer	0.000115	0.000623	CcSEcCtD
Lenalidomide—Agranulocytosis—Doxorubicin—bone cancer	0.000115	0.000622	CcSEcCtD
Lenalidomide—Chills—Methotrexate—bone cancer	0.000115	0.00062	CcSEcCtD
Lenalidomide—Diarrhoea—Cisplatin—bone cancer	0.000113	0.000612	CcSEcCtD
Lenalidomide—Erythema multiforme—Epirubicin—bone cancer	0.000113	0.000611	CcSEcCtD
Lenalidomide—Alopecia—Methotrexate—bone cancer	0.000113	0.00061	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—RB1—bone cancer	0.000113	0.00141	CbGpPWpGaD
Lenalidomide—Bradycardia—Doxorubicin—bone cancer	0.000113	0.000609	CcSEcCtD
Lenalidomide—Mental disorder—Methotrexate—bone cancer	0.000112	0.000605	CcSEcCtD
Lenalidomide—Eye disorder—Epirubicin—bone cancer	0.000112	0.000604	CcSEcCtD
Lenalidomide—Tinnitus—Epirubicin—bone cancer	0.000112	0.000603	CcSEcCtD
Lenalidomide—Erythema—Methotrexate—bone cancer	0.000111	0.000601	CcSEcCtD
Lenalidomide—Malnutrition—Methotrexate—bone cancer	0.000111	0.000601	CcSEcCtD
Lenalidomide—Haemoglobin—Doxorubicin—bone cancer	0.000111	0.000601	CcSEcCtD
Lenalidomide—Flushing—Epirubicin—bone cancer	0.000111	0.0006	CcSEcCtD
Lenalidomide—Cardiac disorder—Epirubicin—bone cancer	0.000111	0.0006	CcSEcCtD
Lenalidomide—Rhinitis—Doxorubicin—bone cancer	0.000111	0.0006	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000111	0.00138	CbGpPWpGaD
Lenalidomide—Haemorrhage—Doxorubicin—bone cancer	0.000111	0.000598	CcSEcCtD
Lenalidomide—Hepatitis—Doxorubicin—bone cancer	0.000111	0.000598	CcSEcCtD
Lenalidomide—Hypoaesthesia—Doxorubicin—bone cancer	0.00011	0.000595	CcSEcCtD
Lenalidomide—Pharyngitis—Doxorubicin—bone cancer	0.00011	0.000594	CcSEcCtD
Lenalidomide—Urinary tract disorder—Doxorubicin—bone cancer	0.000109	0.000591	CcSEcCtD
Lenalidomide—Oedema peripheral—Doxorubicin—bone cancer	0.000109	0.000589	CcSEcCtD
Lenalidomide—Dysgeusia—Methotrexate—bone cancer	0.000109	0.000589	CcSEcCtD
Lenalidomide—Connective tissue disorder—Doxorubicin—bone cancer	0.000109	0.000588	CcSEcCtD
Lenalidomide—Angiopathy—Epirubicin—bone cancer	0.000109	0.000587	CcSEcCtD
Lenalidomide—Urethral disorder—Doxorubicin—bone cancer	0.000109	0.000586	CcSEcCtD
Lenalidomide—Immune system disorder—Epirubicin—bone cancer	0.000108	0.000584	CcSEcCtD
Lenalidomide—Mediastinal disorder—Epirubicin—bone cancer	0.000108	0.000583	CcSEcCtD
Lenalidomide—Back pain—Methotrexate—bone cancer	0.000108	0.000582	CcSEcCtD
Lenalidomide—Chills—Epirubicin—bone cancer	0.000107	0.00058	CcSEcCtD
Lenalidomide—Arrhythmia—Epirubicin—bone cancer	0.000107	0.000578	CcSEcCtD
Lenalidomide—Visual impairment—Doxorubicin—bone cancer	0.000107	0.000576	CcSEcCtD
Lenalidomide—Alopecia—Epirubicin—bone cancer	0.000106	0.000571	CcSEcCtD
Lenalidomide—Vomiting—Cisplatin—bone cancer	0.000105	0.000569	CcSEcCtD
Lenalidomide—Vision blurred—Methotrexate—bone cancer	0.000105	0.000567	CcSEcCtD
Lenalidomide—Mental disorder—Epirubicin—bone cancer	0.000105	0.000566	CcSEcCtD
Lenalidomide—Erythema multiforme—Doxorubicin—bone cancer	0.000105	0.000566	CcSEcCtD
Lenalidomide—Rash—Cisplatin—bone cancer	0.000104	0.000564	CcSEcCtD
Lenalidomide—Dermatitis—Cisplatin—bone cancer	0.000104	0.000563	CcSEcCtD
Lenalidomide—Malnutrition—Epirubicin—bone cancer	0.000104	0.000563	CcSEcCtD
Lenalidomide—Erythema—Epirubicin—bone cancer	0.000104	0.000563	CcSEcCtD
Lenalidomide—Eye disorder—Doxorubicin—bone cancer	0.000103	0.000559	CcSEcCtD
Lenalidomide—Ill-defined disorder—Methotrexate—bone cancer	0.000103	0.000558	CcSEcCtD
Lenalidomide—Tinnitus—Doxorubicin—bone cancer	0.000103	0.000558	CcSEcCtD
Lenalidomide—Anaemia—Methotrexate—bone cancer	0.000103	0.000556	CcSEcCtD
Lenalidomide—Cardiac disorder—Doxorubicin—bone cancer	0.000103	0.000555	CcSEcCtD
Lenalidomide—Flushing—Doxorubicin—bone cancer	0.000103	0.000555	CcSEcCtD
Lenalidomide—Flatulence—Epirubicin—bone cancer	0.000103	0.000555	CcSEcCtD
Lenalidomide—Tension—Epirubicin—bone cancer	0.000102	0.000552	CcSEcCtD
Lenalidomide—Dysgeusia—Epirubicin—bone cancer	0.000102	0.000551	CcSEcCtD
Lenalidomide—Nervousness—Epirubicin—bone cancer	0.000101	0.000547	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000101	0.00126	CbGpPWpGaD
Lenalidomide—Back pain—Epirubicin—bone cancer	0.000101	0.000544	CcSEcCtD
Lenalidomide—Angiopathy—Doxorubicin—bone cancer	0.0001	0.000543	CcSEcCtD
Lenalidomide—Malaise—Methotrexate—bone cancer	0.0001	0.000542	CcSEcCtD
Lenalidomide—Muscle spasms—Epirubicin—bone cancer	0.0001	0.000541	CcSEcCtD
Lenalidomide—Immune system disorder—Doxorubicin—bone cancer	0.0001	0.00054	CcSEcCtD
Lenalidomide—Vertigo—Methotrexate—bone cancer	0.0001	0.00054	CcSEcCtD
Lenalidomide—Mediastinal disorder—Doxorubicin—bone cancer	9.98e-05	0.000539	CcSEcCtD
Lenalidomide—Leukopenia—Methotrexate—bone cancer	9.96e-05	0.000538	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	9.95e-05	0.00124	CbGpPWpGaD
Lenalidomide—Chills—Doxorubicin—bone cancer	9.93e-05	0.000537	CcSEcCtD
Lenalidomide—Arrhythmia—Doxorubicin—bone cancer	9.89e-05	0.000534	CcSEcCtD
Lenalidomide—Nausea—Cisplatin—bone cancer	9.83e-05	0.000531	CcSEcCtD
Lenalidomide—Vision blurred—Epirubicin—bone cancer	9.82e-05	0.00053	CcSEcCtD
Lenalidomide—Alopecia—Doxorubicin—bone cancer	9.78e-05	0.000529	CcSEcCtD
Lenalidomide—Cough—Methotrexate—bone cancer	9.71e-05	0.000525	CcSEcCtD
Lenalidomide—Mental disorder—Doxorubicin—bone cancer	9.7e-05	0.000524	CcSEcCtD
Lenalidomide—Ill-defined disorder—Epirubicin—bone cancer	9.67e-05	0.000522	CcSEcCtD
Lenalidomide—Malnutrition—Doxorubicin—bone cancer	9.64e-05	0.000521	CcSEcCtD
Lenalidomide—Erythema—Doxorubicin—bone cancer	9.64e-05	0.000521	CcSEcCtD
Lenalidomide—Anaemia—Epirubicin—bone cancer	9.63e-05	0.00052	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—KIT—bone cancer	9.58e-05	0.00119	CbGpPWpGaD
Lenalidomide—Agitation—Epirubicin—bone cancer	9.57e-05	0.000517	CcSEcCtD
Lenalidomide—Flatulence—Doxorubicin—bone cancer	9.5e-05	0.000513	CcSEcCtD
Lenalidomide—Chest pain—Methotrexate—bone cancer	9.48e-05	0.000512	CcSEcCtD
Lenalidomide—Myalgia—Methotrexate—bone cancer	9.48e-05	0.000512	CcSEcCtD
Lenalidomide—Arthralgia—Methotrexate—bone cancer	9.48e-05	0.000512	CcSEcCtD
Lenalidomide—Tension—Doxorubicin—bone cancer	9.46e-05	0.000511	CcSEcCtD
Lenalidomide—Dysgeusia—Doxorubicin—bone cancer	9.44e-05	0.00051	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	9.43e-05	0.00118	CbGpPWpGaD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	9.41e-05	0.000508	CcSEcCtD
Lenalidomide—Malaise—Epirubicin—bone cancer	9.39e-05	0.000508	CcSEcCtD
Lenalidomide—Discomfort—Methotrexate—bone cancer	9.36e-05	0.000506	CcSEcCtD
Lenalidomide—Nervousness—Doxorubicin—bone cancer	9.36e-05	0.000506	CcSEcCtD
Lenalidomide—Vertigo—Epirubicin—bone cancer	9.36e-05	0.000506	CcSEcCtD
Lenalidomide—Syncope—Epirubicin—bone cancer	9.34e-05	0.000505	CcSEcCtD
Lenalidomide—Leukopenia—Epirubicin—bone cancer	9.32e-05	0.000504	CcSEcCtD
Lenalidomide—Back pain—Doxorubicin—bone cancer	9.32e-05	0.000504	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—NDUFA12—bone cancer	9.28e-05	0.00116	CbGpPWpGaD
Lenalidomide—Muscle spasms—Doxorubicin—bone cancer	9.27e-05	0.000501	CcSEcCtD
Lenalidomide—Palpitations—Epirubicin—bone cancer	9.21e-05	0.000497	CcSEcCtD
Lenalidomide—Confusional state—Methotrexate—bone cancer	9.16e-05	0.000495	CcSEcCtD
Lenalidomide—Loss of consciousness—Epirubicin—bone cancer	9.16e-05	0.000495	CcSEcCtD
Lenalidomide—Cough—Epirubicin—bone cancer	9.09e-05	0.000491	CcSEcCtD
Lenalidomide—Vision blurred—Doxorubicin—bone cancer	9.08e-05	0.000491	CcSEcCtD
Lenalidomide—Infection—Methotrexate—bone cancer	9.03e-05	0.000488	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—BRAF—bone cancer	9e-05	0.00112	CbGpPWpGaD
Lenalidomide—Hypertension—Epirubicin—bone cancer	8.99e-05	0.000486	CcSEcCtD
Lenalidomide—Ill-defined disorder—Doxorubicin—bone cancer	8.94e-05	0.000483	CcSEcCtD
Lenalidomide—Nervous system disorder—Methotrexate—bone cancer	8.91e-05	0.000481	CcSEcCtD
Lenalidomide—Anaemia—Doxorubicin—bone cancer	8.91e-05	0.000481	CcSEcCtD
Lenalidomide—Thrombocytopenia—Methotrexate—bone cancer	8.89e-05	0.000481	CcSEcCtD
Lenalidomide—Arthralgia—Epirubicin—bone cancer	8.87e-05	0.000479	CcSEcCtD
Lenalidomide—Chest pain—Epirubicin—bone cancer	8.87e-05	0.000479	CcSEcCtD
Lenalidomide—Myalgia—Epirubicin—bone cancer	8.87e-05	0.000479	CcSEcCtD
Lenalidomide—Agitation—Doxorubicin—bone cancer	8.86e-05	0.000479	CcSEcCtD
Lenalidomide—Anxiety—Epirubicin—bone cancer	8.84e-05	0.000477	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	8.83e-05	0.0011	CbGpPWpGaD
Lenalidomide—Skin disorder—Methotrexate—bone cancer	8.82e-05	0.000477	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	8.81e-05	0.000476	CcSEcCtD
Lenalidomide—Hyperhidrosis—Methotrexate—bone cancer	8.78e-05	0.000474	CcSEcCtD
Lenalidomide—Discomfort—Epirubicin—bone cancer	8.76e-05	0.000473	CcSEcCtD
Lenalidomide—Malaise—Doxorubicin—bone cancer	8.69e-05	0.00047	CcSEcCtD
Lenalidomide—Dry mouth—Epirubicin—bone cancer	8.67e-05	0.000469	CcSEcCtD
Lenalidomide—Vertigo—Doxorubicin—bone cancer	8.66e-05	0.000468	CcSEcCtD
Lenalidomide—Anorexia—Methotrexate—bone cancer	8.66e-05	0.000468	CcSEcCtD
Lenalidomide—Syncope—Doxorubicin—bone cancer	8.64e-05	0.000467	CcSEcCtD
Lenalidomide—Leukopenia—Doxorubicin—bone cancer	8.63e-05	0.000466	CcSEcCtD
Lenalidomide—Confusional state—Epirubicin—bone cancer	8.57e-05	0.000463	CcSEcCtD
Lenalidomide—Palpitations—Doxorubicin—bone cancer	8.52e-05	0.00046	CcSEcCtD
Lenalidomide—Oedema—Epirubicin—bone cancer	8.5e-05	0.000459	CcSEcCtD
Lenalidomide—Hypotension—Methotrexate—bone cancer	8.49e-05	0.000459	CcSEcCtD
Lenalidomide—Loss of consciousness—Doxorubicin—bone cancer	8.47e-05	0.000458	CcSEcCtD
Lenalidomide—Infection—Epirubicin—bone cancer	8.45e-05	0.000456	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	8.44e-05	0.00105	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	8.41e-05	0.00105	CbGpPWpGaD
Lenalidomide—Cough—Doxorubicin—bone cancer	8.41e-05	0.000454	CcSEcCtD
Lenalidomide—Shock—Epirubicin—bone cancer	8.36e-05	0.000452	CcSEcCtD
Lenalidomide—Nervous system disorder—Epirubicin—bone cancer	8.34e-05	0.00045	CcSEcCtD
Lenalidomide—Thrombocytopenia—Epirubicin—bone cancer	8.32e-05	0.00045	CcSEcCtD
Lenalidomide—Hypertension—Doxorubicin—bone cancer	8.32e-05	0.00045	CcSEcCtD
Lenalidomide—Tachycardia—Epirubicin—bone cancer	8.3e-05	0.000448	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Methotrexate—bone cancer	8.28e-05	0.000447	CcSEcCtD
Lenalidomide—Skin disorder—Epirubicin—bone cancer	8.26e-05	0.000446	CcSEcCtD
Lenalidomide—Hyperhidrosis—Epirubicin—bone cancer	8.22e-05	0.000444	CcSEcCtD
Lenalidomide—Insomnia—Methotrexate—bone cancer	8.22e-05	0.000444	CcSEcCtD
Lenalidomide—Arthralgia—Doxorubicin—bone cancer	8.21e-05	0.000443	CcSEcCtD
Lenalidomide—Myalgia—Doxorubicin—bone cancer	8.21e-05	0.000443	CcSEcCtD
Lenalidomide—Chest pain—Doxorubicin—bone cancer	8.21e-05	0.000443	CcSEcCtD
Lenalidomide—Anxiety—Doxorubicin—bone cancer	8.18e-05	0.000442	CcSEcCtD
Lenalidomide—Paraesthesia—Methotrexate—bone cancer	8.16e-05	0.000441	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	8.15e-05	0.00044	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—MMP9—bone cancer	8.13e-05	0.00101	CbGpPWpGaD
Lenalidomide—Discomfort—Doxorubicin—bone cancer	8.11e-05	0.000438	CcSEcCtD
Lenalidomide—Anorexia—Epirubicin—bone cancer	8.1e-05	0.000438	CcSEcCtD
Lenalidomide—Dyspnoea—Methotrexate—bone cancer	8.1e-05	0.000438	CcSEcCtD
Lenalidomide—Somnolence—Methotrexate—bone cancer	8.08e-05	0.000436	CcSEcCtD
Lenalidomide—Dry mouth—Doxorubicin—bone cancer	8.03e-05	0.000434	CcSEcCtD
Lenalidomide—Dyspepsia—Methotrexate—bone cancer	8e-05	0.000432	CcSEcCtD
Lenalidomide—Hypotension—Epirubicin—bone cancer	7.94e-05	0.000429	CcSEcCtD
Lenalidomide—Confusional state—Doxorubicin—bone cancer	7.93e-05	0.000429	CcSEcCtD
Lenalidomide—Decreased appetite—Methotrexate—bone cancer	7.9e-05	0.000427	CcSEcCtD
Lenalidomide—Oedema—Doxorubicin—bone cancer	7.87e-05	0.000425	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Methotrexate—bone cancer	7.84e-05	0.000424	CcSEcCtD
Lenalidomide—Fatigue—Methotrexate—bone cancer	7.83e-05	0.000423	CcSEcCtD
Lenalidomide—Infection—Doxorubicin—bone cancer	7.81e-05	0.000422	CcSEcCtD
Lenalidomide—Pain—Methotrexate—bone cancer	7.77e-05	0.00042	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Epirubicin—bone cancer	7.75e-05	0.000418	CcSEcCtD
Lenalidomide—Shock—Doxorubicin—bone cancer	7.74e-05	0.000418	CcSEcCtD
Lenalidomide—Nervous system disorder—Doxorubicin—bone cancer	7.71e-05	0.000417	CcSEcCtD
Lenalidomide—Thrombocytopenia—Doxorubicin—bone cancer	7.7e-05	0.000416	CcSEcCtD
Lenalidomide—Insomnia—Epirubicin—bone cancer	7.69e-05	0.000415	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—NT5C3A—bone cancer	7.69e-05	0.000959	CbGpPWpGaD
Lenalidomide—Tachycardia—Doxorubicin—bone cancer	7.68e-05	0.000415	CcSEcCtD
Lenalidomide—Skin disorder—Doxorubicin—bone cancer	7.64e-05	0.000413	CcSEcCtD
Lenalidomide—Paraesthesia—Epirubicin—bone cancer	7.63e-05	0.000412	CcSEcCtD
Lenalidomide—Hyperhidrosis—Doxorubicin—bone cancer	7.6e-05	0.000411	CcSEcCtD
Lenalidomide—Dyspnoea—Epirubicin—bone cancer	7.58e-05	0.000409	CcSEcCtD
Lenalidomide—Somnolence—Epirubicin—bone cancer	7.56e-05	0.000408	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—MDM2—bone cancer	7.54e-05	0.00094	CbGpPWpGaD
Lenalidomide—Anorexia—Doxorubicin—bone cancer	7.5e-05	0.000405	CcSEcCtD
Lenalidomide—Feeling abnormal—Methotrexate—bone cancer	7.49e-05	0.000404	CcSEcCtD
Lenalidomide—Dyspepsia—Epirubicin—bone cancer	7.48e-05	0.000404	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Methotrexate—bone cancer	7.43e-05	0.000401	CcSEcCtD
Lenalidomide—Decreased appetite—Epirubicin—bone cancer	7.39e-05	0.000399	CcSEcCtD
Lenalidomide—Hypotension—Doxorubicin—bone cancer	7.35e-05	0.000397	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Epirubicin—bone cancer	7.34e-05	0.000397	CcSEcCtD
Lenalidomide—Fatigue—Epirubicin—bone cancer	7.33e-05	0.000396	CcSEcCtD
Lenalidomide—Pain—Epirubicin—bone cancer	7.27e-05	0.000393	CcSEcCtD
Lenalidomide—Constipation—Epirubicin—bone cancer	7.27e-05	0.000393	CcSEcCtD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	7.26e-05	0.000905	CbGpPWpGaD
Lenalidomide—Urticaria—Methotrexate—bone cancer	7.22e-05	0.00039	CcSEcCtD
Lenalidomide—Body temperature increased—Methotrexate—bone cancer	7.18e-05	0.000388	CcSEcCtD
Lenalidomide—Abdominal pain—Methotrexate—bone cancer	7.18e-05	0.000388	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Doxorubicin—bone cancer	7.17e-05	0.000387	CcSEcCtD
Lenalidomide—Insomnia—Doxorubicin—bone cancer	7.11e-05	0.000384	CcSEcCtD
Lenalidomide—Paraesthesia—Doxorubicin—bone cancer	7.06e-05	0.000382	CcSEcCtD
Lenalidomide—Dyspnoea—Doxorubicin—bone cancer	7.01e-05	0.000379	CcSEcCtD
Lenalidomide—Feeling abnormal—Epirubicin—bone cancer	7.01e-05	0.000378	CcSEcCtD
Lenalidomide—Somnolence—Doxorubicin—bone cancer	6.99e-05	0.000378	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Epirubicin—bone cancer	6.95e-05	0.000376	CcSEcCtD
Lenalidomide—Dyspepsia—Doxorubicin—bone cancer	6.92e-05	0.000374	CcSEcCtD
Lenalidomide—Decreased appetite—Doxorubicin—bone cancer	6.84e-05	0.000369	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Doxorubicin—bone cancer	6.79e-05	0.000367	CcSEcCtD
Lenalidomide—Fatigue—Doxorubicin—bone cancer	6.78e-05	0.000366	CcSEcCtD
Lenalidomide—Urticaria—Epirubicin—bone cancer	6.75e-05	0.000365	CcSEcCtD
Lenalidomide—Pain—Doxorubicin—bone cancer	6.73e-05	0.000363	CcSEcCtD
Lenalidomide—Constipation—Doxorubicin—bone cancer	6.73e-05	0.000363	CcSEcCtD
Lenalidomide—Abdominal pain—Epirubicin—bone cancer	6.72e-05	0.000363	CcSEcCtD
Lenalidomide—Body temperature increased—Epirubicin—bone cancer	6.72e-05	0.000363	CcSEcCtD
Lenalidomide—Hypersensitivity—Methotrexate—bone cancer	6.69e-05	0.000362	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—NDUFA12—bone cancer	6.58e-05	0.00082	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—EGFR—bone cancer	6.57e-05	0.000819	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—JUN—bone cancer	6.56e-05	0.000817	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	6.54e-05	0.000816	CbGpPWpGaD
Lenalidomide—Asthenia—Methotrexate—bone cancer	6.52e-05	0.000352	CcSEcCtD
Lenalidomide—Feeling abnormal—Doxorubicin—bone cancer	6.48e-05	0.00035	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Doxorubicin—bone cancer	6.43e-05	0.000348	CcSEcCtD
Lenalidomide—Pruritus—Methotrexate—bone cancer	6.43e-05	0.000347	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—MMP9—bone cancer	6.38e-05	0.000795	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Epirubicin—bone cancer	6.26e-05	0.000338	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	6.26e-05	0.00078	CbGpPWpGaD
Lenalidomide—Urticaria—Doxorubicin—bone cancer	6.25e-05	0.000338	CcSEcCtD
Lenalidomide—Body temperature increased—Doxorubicin—bone cancer	6.22e-05	0.000336	CcSEcCtD
Lenalidomide—Abdominal pain—Doxorubicin—bone cancer	6.22e-05	0.000336	CcSEcCtD
Lenalidomide—Diarrhoea—Methotrexate—bone cancer	6.22e-05	0.000336	CcSEcCtD
Lenalidomide—Asthenia—Epirubicin—bone cancer	6.1e-05	0.00033	CcSEcCtD
Lenalidomide—Pruritus—Epirubicin—bone cancer	6.01e-05	0.000325	CcSEcCtD
Lenalidomide—Dizziness—Methotrexate—bone cancer	6.01e-05	0.000325	CcSEcCtD
Lenalidomide—Diarrhoea—Epirubicin—bone cancer	5.82e-05	0.000314	CcSEcCtD
Lenalidomide—Hypersensitivity—Doxorubicin—bone cancer	5.8e-05	0.000313	CcSEcCtD
Lenalidomide—Vomiting—Methotrexate—bone cancer	5.78e-05	0.000312	CcSEcCtD
Lenalidomide—Rash—Methotrexate—bone cancer	5.73e-05	0.000309	CcSEcCtD
Lenalidomide—Dermatitis—Methotrexate—bone cancer	5.72e-05	0.000309	CcSEcCtD
Lenalidomide—Headache—Methotrexate—bone cancer	5.69e-05	0.000307	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	5.69e-05	0.000709	CbGpPWpGaD
Lenalidomide—Asthenia—Doxorubicin—bone cancer	5.64e-05	0.000305	CcSEcCtD
Lenalidomide—Dizziness—Epirubicin—bone cancer	5.62e-05	0.000304	CcSEcCtD
Lenalidomide—Pruritus—Doxorubicin—bone cancer	5.57e-05	0.000301	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—TP53—bone cancer	5.52e-05	0.000688	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—NT5C3A—bone cancer	5.45e-05	0.00068	CbGpPWpGaD
Lenalidomide—Vomiting—Epirubicin—bone cancer	5.41e-05	0.000292	CcSEcCtD
Lenalidomide—Nausea—Methotrexate—bone cancer	5.4e-05	0.000292	CcSEcCtD
Lenalidomide—Diarrhoea—Doxorubicin—bone cancer	5.38e-05	0.000291	CcSEcCtD
Lenalidomide—Rash—Epirubicin—bone cancer	5.36e-05	0.00029	CcSEcCtD
Lenalidomide—Dermatitis—Epirubicin—bone cancer	5.36e-05	0.000289	CcSEcCtD
Lenalidomide—Headache—Epirubicin—bone cancer	5.33e-05	0.000288	CcSEcCtD
Lenalidomide—Dizziness—Doxorubicin—bone cancer	5.2e-05	0.000281	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—EGFR—bone cancer	5.15e-05	0.000643	CbGpPWpGaD
Lenalidomide—Nausea—Epirubicin—bone cancer	5.05e-05	0.000273	CcSEcCtD
Lenalidomide—Vomiting—Doxorubicin—bone cancer	5e-05	0.00027	CcSEcCtD
Lenalidomide—Rash—Doxorubicin—bone cancer	4.96e-05	0.000268	CcSEcCtD
Lenalidomide—Dermatitis—Doxorubicin—bone cancer	4.96e-05	0.000268	CcSEcCtD
Lenalidomide—Headache—Doxorubicin—bone cancer	4.93e-05	0.000266	CcSEcCtD
Lenalidomide—Nausea—Doxorubicin—bone cancer	4.67e-05	0.000252	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	4.64e-05	0.000578	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	4.47e-05	0.000557	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	4.47e-05	0.000557	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TP53—bone cancer	4.33e-05	0.00054	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	4.03e-05	0.000503	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ENO2—bone cancer	4.02e-05	0.000501	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	3.75e-05	0.000468	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—DHFR—bone cancer	3.73e-05	0.000465	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ENO2—bone cancer	3.37e-05	0.00042	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	3.17e-05	0.000395	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—DHFR—bone cancer	3.12e-05	0.00039	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GNA11—bone cancer	2.92e-05	0.000364	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TGFBR2—bone cancer	2.7e-05	0.000337	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	2.66e-05	0.000332	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP3A4—bone cancer	2.65e-05	0.00033	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ENO2—bone cancer	2.39e-05	0.000298	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GSTP1—bone cancer	2.26e-05	0.000282	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—DHFR—bone cancer	2.21e-05	0.000276	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GNA11—bone cancer	2.07e-05	0.000258	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP3A4—bone cancer	1.88e-05	0.000234	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—KIT—bone cancer	1.84e-05	0.00023	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—BRAF—bone cancer	1.73e-05	0.000216	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTP1—bone cancer	1.6e-05	0.0002	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MDM2—bone cancer	1.45e-05	0.000181	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—EGFR—bone cancer	9.93e-06	0.000124	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PTGS2—bone cancer	8.31e-06	0.000104	CbGpPWpGaD
